Balancing GLP-1 Quality With Demand

The global market for GLP-1 drugs is forecasted to bring in $156.71 billion in 2030, nearly tripling in size from $53.46 billion in 2025, with an estimated 17.46% CAGR.* Recent surges in demand put some GLP-1 drugs on shortage lists, leading to compounded versions that took away market share from major players and introduced quality concerns. To gear up for the demand ahead, manufacturers need to innovate—yes—but what other changes to manufacturing and quality control processes need to be made to ensure quantity doesn’t impact quality?

Join experts Doug Bakan, Ph.D., chief technology officer at Kailera Therapeutics; Deepa Nagpal, founder of SygnifyQ; and Hyung Heon Kim, CEO of MetaVia; who dove into optimizing both manufacturing strategies and quality control to ensure a balance with GLP-1 agonists. These panelists explored peptide manufacturing techniques, strengthening the supply chain, assays for purity/activity, technology transfer to scale partners, and so much more. Learn how technology on both the production and analytical side can lead to quantity/quality GLP-1 agonists far into the future.

This Pharmaceutical Online Live event was hosted by Katie Anderson and is free to attend, thanks to the event sponsor, Waters Corporation.